Tumor Biology

, Volume 36, Issue 11, pp 8271–8272 | Cite as

The STORM trial and beyond: narrowing the horizon of adjuvant sorafenib for postoperative hepatocellular carcinoma

  • Jian-Hong Zhong

China is a region with high prevalence of hepatocellular carcinoma (HCC) [1]. With improvements in surgical technique and perioperative care, hepatic resection is the first-line therapy for many patients in early HCC as well as intermediate or advanced disease [2, 3]. However, tumor recurrence is common and jeopardizes patients’ prognosis. Hepatic resection is associated with tumor recurrence rates of up to 74 % at 5 years [4]. Due to the most frequent cause of postoperative death among patients with HCC is tumor recurrence in the remnant liver, the long-term prognosis after hepatic resection remains unsatisfactory. Therefore, prevention of tumor recurrence via postoperative or adjuvant treatments is an important unmet clinical requirement in patients with HCC. Despite all this, no postoperative or adjuvant treatment is recommended by official guidelines until now [5, 6].

Just under such a background, the STORM trial was designed to assess the efficacy and safety of adjuvant sorafenib...


Adjuvant Hepatocellular carcinoma Sorafenib 


Compliance with ethical standards

Conflicts of interest



  1. 1.
    Chen W, Zheng R, Zhang S, et al. Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res. 2013;25(1):10–21.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Zhong JH, Rodriguez AC, Ke Y, Wang YY, Wang L, Li LQ. Hepatic resection as a safe and effective treatment for hepatocellular carcinoma involving a single large tumor, multiple tumors, or macrovascular invasion. Medicine (Baltimore). 2015;94(3):e396.CrossRefGoogle Scholar
  3. 3.
    Qi X, Wang D, Su C, Li H, Guo X. Hepatic resection versus transarterial chemoembolization for the initial treatment of hepatocellular carcinoma: a systematic review and meta-analysis. Oncotarget. 2015;6(21):18715–33.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Zhong JH, Ke Y, Gong WF, et al. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann Surg. 2014;260(2):329–40.CrossRefPubMedGoogle Scholar
  5. 5.
    European Association for Study of Liver. European organisation for research and treatment of cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012;48(5):599–641.CrossRefGoogle Scholar
  6. 6.
    Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.CrossRefPubMedGoogle Scholar
  8. 8.
    Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.CrossRefPubMedGoogle Scholar
  9. 9.
    Zhong JH, You XM, Lu SD, et al. Historical comparison of overall survival after hepatic resection for patients with large and/or Multinodular hepatocellular carcinoma. Medicine (Baltimore). 2015;94(35):e1426.CrossRefGoogle Scholar
  10. 10.
    Zhong JH, Lu SD, Wang YY, Ma L, Li LQ. Intermediate-stage HCC—upfront resection can be feasible. Nat Rev Clin Oncol. 2015;12(5):295.CrossRefGoogle Scholar
  11. 11.
    Zhong JH. Nucleos(t)ide analogue therapy for HBV-related HCC after hepatic resection: clinical benefits and unanswered questions. Tumour Biol. 2014;35(12):12779–84.CrossRefPubMedGoogle Scholar
  12. 12.
    Zhong JH, Zhong QL, Li LQ, Li H. Adjuvant and chemopreventive therapies for resectable hepatocellular carcinoma: a literature review. Tumour Biol. 2014;35(10):9459–68.CrossRefPubMedGoogle Scholar
  13. 13.
    Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16(13):1344–54.CrossRefPubMedGoogle Scholar
  14. 14.
    Wang SN, Chuang SC, Lee KT. Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: a pilot study. Hepatol Res. 2014;44(5):523–31.CrossRefPubMedGoogle Scholar
  15. 15.
    Zhang W, Zhao G, Wei K, et al. Adjuvant sorafenib reduced mortality and prolonged overall survival and post-recurrence survival in hepatocellular carcinoma patients after curative resection: a single-center experience. Biosci Trends. 2014;8(6):333–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57(4):821–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Galle PR. Sorafenib in advanced hepatocellular carcinoma—We have won a battle not the war. J Hepatol. 2008;49(5):871–3.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Hepatobiliary Surgery DepartmentAffiliated Tumor Hospital of Guangxi Medical UniversityNanningChina
  2. 2.Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research CenterNanningChina

Personalised recommendations